Latest Articles about SNY

Good News for InterMune - Analyst Blog

Zacks Equity Research — Tue, 18 Jun 2013 00:30:01 Z

InterMune, Inc. ( ITMN ) recently received encouraging news when the pricing and reimbursement conditions for its sole marketed drug, Esbriet, were approved by the Board of the Italian Drug

Sanofi's Fluzone Quadrivalent Gets FDA Nod - Analyst Blog

Zacks Equity Research — Thu, 13 Jun 2013 19:30:01 Z

Sanofi ( SNY ) recently announced that the US Food and Drug Administration (FDA) has cleared its quadrivalent formulation of Fluzone. The four-strain influenza vaccine has been approved for

CHMP Positive on Sanofi's Lantus - Analyst Blog

Zacks Equity Research — Wed, 12 Jun 2013 02:13:01 Z

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently issued a positive opinion related to Sanofi 's ( SNY ) diabetes drug, Lantus.

Glaxo Reports Disappointing Tykerb Data - Analyst Blog

Zacks Equity Research — Tue, 11 Jun 2013 02:29:21 Z

GlaxoSmithKline ( GSK ) recently announced disappointing data from a global phase III study evaluating the use of Tykerb in patients suffering from human epidermal growth factor receptor 2

FDA Panel Positive on GSK's Avandia - Analyst Blog

Zacks Equity Research — Sat, 08 Jun 2013 01:29:00 Z

Good news recently flowed in at GlaxoSmithKline ( GSK ) when the joint advisory committee (comprising Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk

Encouraging data from Bristol-Myers - Analyst Blog

Zacks Equity Research — Wed, 05 Jun 2013 20:30:30 Z

Bristol-Myers Squibb Company ( BMY ) recently announced encouraging data on its oncology candidate nivolumab from a phase I dose-ranging trial (study 004: n=86). The study evaluated the

Pipeline Setbacks at Sanofi - Analyst Blog

Zacks Equity Research — Wed, 05 Jun 2013 01:31:06 Z

Recently, Sanofi ( SNY ) announced negative top-line phase III data on oncology candidate, iniparib and anticoagulant, otamixaban. Both phase III studies did not meet the primary endpoint.

GSK/Genmab Report Positive Arzerra Data - Analyst Blog

Zacks Equity Research — Sat, 01 Jun 2013 02:29:25 Z

GlaxoSmithKline ( GSK ) and partner Genmab recently announced encouraging top-line data from a phase III study (n = 447) which is evaluating oncology drug, Arzerra (ofatumumab). The study

Mixed News on Merck's Pipeline - Analyst Blog

Zacks Equity Research — Wed, 29 May 2013 02:29:12 Z

Merck ( MRK ) recently announced mixed news on the pipeline front. While the company received support from the US Food and Drug Administration's (FDA) Central Nervous System Drugs Advisory

Back to Neutral on Hospira - Analyst Blog

Zacks Equity Research — Tue, 28 May 2013 22:28:02 Z

We are reverting to a Neutral recommendation on Hospira Inc. ( HSP ) from Underperform. Our target price is $37.00. The stock carries a Zacks Rank #3 (Hold) in the short run. Why the

Encouraging News for Peregrine Pharma - Analyst Blog

Zacks Equity Research — Fri, 24 May 2013 20:28:57 Z

Peregrine Pharmaceuticals ( PPHM ) recently received encouraging news when the company announced that the US Food and Drug Administration (FDA) has agreed on the design for the phase III

Encouraging News for Peregrine Pharma - Analyst Blog

Zacks Equity Research — Fri, 24 May 2013 03:26:41 Z

Peregrine Pharmaceuticals ( PPHM ) recently received encouraging news when the company announced that the US Food and Drug Administration (FDA) has agreed on the design for the phase III

Sanofi/REGN's Dupilumab Data Published - Analyst Blog

Zacks Equity Research — Thu, 23 May 2013 00:25:37 Z

Sanofi ( SNY ) and partner Regeneron Pharmaceuticals, Inc. ( REGN ) recently announced that positive data from a phase IIa study evaluating dupilumab (REGN668/SAR231893) for

Sanofi/REGN Commence Enrollment - Analyst Blog

Zacks Equity Research — Thu, 16 May 2013 01:28:51 Z

Sanofi ( SNY ) and partner Regeneron Pharmaceuticals, Inc. ( REGN ) recently announced that they started enrolling patients for two phase III trials (SARIL-RA COMPARE and SARIL-RA

FDA Accepts Merck BLA - Analyst Blog

Zacks Equity Research — Wed, 15 May 2013 20:30:44 Z

Merck ( MRK ) recently announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for its ragweed pollen (ambrosia artemisiifolia)